Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs At Risk

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-30

Study Completion Date

2024-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate performance and clinical applicability of AI-assisted radiotherapy contouring software for thoracic organs at risk. The main question it aims to answer is:

• Does AI-assisted contouring (AI contouring with manual modification) offer greater accuracy and time efficiency compared to manual contouring? After screening, the qualified participants' thoracic CT images will be anonymized and segmented using three methods: manual, AI (AI-only), and AI-assisted contouring. The researchers will compare the results generated by the three different contouring methods with the ground truth established by expert consensus, in order to evaluate both accuracy and time-related parameters

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC

NCT02688036

Carcinoma, Small Cell Lung Neoplasms

UNKNOWN PHASE3

A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery

NCT06686459

Breast Cancer Invasive

RECRUITING NA

Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer

NCT06730295

Lung Cancer (NSCLC)

RECRUITING PHASE2

The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy

NCT06342323

Lung Cancer Liver Cancer Pancreatic Cancer +1 more

RECRUITING

Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02790190

Lung Neoplasms

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Breast Cancer Esophageal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Independent manual contouring

Manual contouring refers to physicians using the brush tool on the contouring platform to segment thoracic organs at risk manually, without the use of auto-segmentation tools.

No interventions assigned to this group

AI contouring

AI contouring refers to the auto-segmentation results generated by the Res-SE Net model, with the model integrated into the auto-segmentation software.

No interventions assigned to this group

AI-assisted contouring

After generating the AI contouring results, investigators will import them into the contouring platform and perform manual modifications, producing the AI-assisted contouring.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 years old, no gender limit.
2. Patients diagnosed with breast cancer, lung cancer, or esophageal cancer, who are scheduled for chest CT scanning followed by thoracic radiotherapy.
3. CT slice thickness ≤5mm.
4. Patients understand the goal of the trial, are willing to attend the trial and sign the informed consent.

Exclusion Criteria

1. Congenital malformations or abnormal anatomical structures resulting from non-tumor factors in the scan area.
2. Artifact, prosthesis or implantation causing images undistinguishable.
3. CT images not conforming to DICOM standards.
4. Investigators consider not suitable.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No